ARS Pharmaceuticals, Inc. SPRY Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$197.98M-15.6% | -$171.3M-114% | -$80.04M-66.7% | -$48.02M-207% | -$15.65M-296% | ||
| $1.48M+8.6% | $1.37M+39.6% | $979K+60.8% | $609K+75.0% | $348K+341% | ||
| $24.22M+9.6% | $22.1M+7.1% | $20.62M+11.3% | $18.52M+12.1% | $16.52M+13.6% | ||
| —— | —— | $35.78M+58.7% | $22.55M+142% | $9.3M+13.8% | ||
| $14.79M-35.5% | $22.95M+20.8% | $18.99M-1.0% | $19.18M+33.2% | $14.39M+142% | ||
| —— | —— | $35.61M+22.9% | $28.98M+50.7% | $19.24M+17.2% | ||
| -$4.93M-651% | -$656K-110% | $6.88M-18.6% | $8.45M-28.7% | $11.85M+91.5% | ||
| —— | —— | —— | —— | —— | ||
| -$201K+42.6% | -$350K-120% | $1.79M-3.0% | $1.85M-1.6% | $1.88M-10.1% | ||
| -$175.07M-2.5% | -$170.87M-100% | -$85.38M-61.7% | -$52.8M-158% | -$20.48M-251% | ||
| $248K-26.8% | $339K-47.1% | $641K+9.8% | $584K+2.3% | $571K+1.4% | ||
| $222.4M-8.1% | $242.03M-32.1% | $356.61M+31.7% | $270.72M-17.2% | $326.95M-8.2% | ||
| $286M-6.8% | $307M+2.7% | $299M+10.1% | $271.5M+1.9% | $266.5M+3.3% | ||
| —— | —— | —— | —— | —— | ||
| $5.02M-11.7% | $5.68M+4.5% | $5.43M-3.6% | $5.64M+61.8% | $3.48M+15.5% | ||
| $104.03M-0.5% | $104.6M-40.0% | $174.38M+132% | $75.02M+3.0% | $72.87M+0.6% | ||
| -$15.54M-63.6% | -$9.5M— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| $4.55M-17.6% | $5.52M-8.9% | $6.06M-10.8% | $6.8M— | —— | ||
| -$4.93M-651% | -$656K-110% | $6.88M-18.6% | $8.45M-28.7% | $11.85M+91.5% | ||
| —— | —— | —— | —— | —— | ||
| $222.4M-8.1% | $242.03M-32.1% | $356.61M+31.7% | $270.72M-17.2% | $326.95M-8.2% | ||
| $286M-6.8% | $307M+2.7% | $299M+10.1% | $271.5M+1.9% | $266.5M+3.3% | ||
| $5.02M-11.7% | $5.68M+4.5% | $5.43M-3.6% | $5.64M+61.8% | $3.48M+15.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$201K+42.6% | -$350K-120% | $1.79M-3.0% | $1.85M-1.6% | $1.88M-10.1% | ||
| -$175.32M-2.4% | -$171.21M-99.0% | -$86.02M-61.1% | -$53.38M-154% | -$21.06M-262% | ||
| -$175.32M-2.4% | -$171.21M-99.0% | -$86.02M-61.1% | -$53.38M-154% | -$21.06M-262% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ARS Pharmaceuticals, Inc. generate?
- ARS Pharmaceuticals, Inc. (SPRY) generated -$175.1M in operating cash flow over the trailing twelve months.
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- After $248.0K of capital expenditures, ARS Pharmaceuticals, Inc.'s free cash flow was -$175.3M over the trailing twelve months, down 732.7% year over year.
- Where does ARS Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
